Pinch-zoom for details.
The offering
Price range
$10–$12
per share
Shares offered
2.27M
+341K over-allotment option
Raise at $11 midpoint
$25.0M
2,272,727 × $11, before fees
What the company does
Development-stage medical device company working on a synthetic graft (MAVERICS) for coronary artery bypass surgery.
Things to weigh
- Loss-making: net loss of $10.2M in FY2025.
The numbers
| $ | FY2024 | FY2025 | YoY |
|---|
| Operating result | (11.3M) | (10.2M) | +10.1% |
| Net result | (11.4M) | (10.2M) | +10.0% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
Risks
- We have incurred significant operating losses every year since our inception and have not generated any revenue
- Our financial performance will depend on the commercial success of our current product candidate and future products
- There is substantial doubt about our ability to continue as a going concern
- Even if this offering is successful, we will require additional capital to fund our operations, which may not be available on acceptable terms…
- We may encounter difficulties in managing our growth, which could negatively impact our operations
- Unstable market and economic conditions, including as a result of geopolitical events, may have serious adverse consequences on our business…
The filing's own risk-factor headings, shortened.
Strategy
- Scalability: Our finished MAVERICS grafts are not cultured, offering commercial-scale manufacturing
- Off-the-Shelf: Our grafts for CABG are shipped sterile and in final packaging
- Long-Term Shelf Stability
- Ease of Implant: Our product is easily implanted by the surgeon
- No Surgical Harvesting: Using our graft removes the need to harvest an autologous vessel from the patient, resulting in a faster procedure…
- Consistent Uniformity and Surgical Handling
The filing's own strategy headings, shortened.
Source: Medical 21, Inc.'s Form S-1/A, filed with the SEC on Mar 20, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.